Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.
You may also be interested in...
Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage
Exondys 51 has been met with recommendations for restrictions by many insurers, but after consultations with experts and Sarepta execs coverage is expanding.
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
The latest drug development news and highlights from our FDA Performance Tracker.
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Steroid treatment like Emflaza is considered standard of care and availability of other products may make payer discussions difficult.